Jump to main content
Jump to site search

Issue 10, 2018
Previous Article Next Article

Troxerutin subdues hepatic tumorigenesis via disrupting the MDM2–p53 interaction

Author affiliations

Abstract

Hepatocellular carcinoma (HCC) is the leading cause of cancer death worldwide that lacks proper medical prognosis and treatment. In the present study, the anti-tumoral potential of troxerutin (TX), an ethnomedicine, was examined in relation to its effects on the promoter 2-acetylaminofluorene (2-AAF) in N-nitrosodiethylamine (NDEA) initiated HCC, as compared to its effects on HCC induced by NDEA alone. Liver samples from each experimental group were collected and evaluated for histological, biochemical and cellular characterization. The protein expressions of apoptotic and cell proliferation markers were determined via immunohistochemistry and western blotting. Molecular docking was also performed to delineate the inhibitory mechanism of TX on HCC. The results show that only higher doses of TX showed a significant reduction in the incidence of hepatic nodule formation, and they also counteracted NDEA plus 2-AAF induced alterations in the enzymic status. The frequencies of glutathione-S-transferase and proliferating cell nuclear antigen, markers of S phase progression, were markedly reduced during TX treatment. TX also modulated the imbalance in the MDM2–p53 interaction. The molecular docking results confirmed the interaction of TX with the upstream kinases that regulate apoptosis. This study provides evidence that a copious dose of TX is required to counteract the differential mitoinhibitory effect of 2-AAF in NDEA initiated hepatomas, and TX exhibits an anti-tumoral effect via suppressing oxidative stress, regulating liver function enzymes, inhibiting inflammatory responses and modulating MDM2–p53 interactions, thus inducing apoptosis, and thereby suggesting that TX may provide promising therapeutic effects for the chemoprevention of HCC.

Graphical abstract: Troxerutin subdues hepatic tumorigenesis via disrupting the MDM2–p53 interaction

Back to tab navigation

Supplementary files

Publication details

The article was received on 04 Jun 2018, accepted on 12 Sep 2018 and first published on 27 Sep 2018


Article type: Paper
DOI: 10.1039/C8FO01111G
Citation: Food Funct., 2018,9, 5336-5349
  •   Request permissions

    Troxerutin subdues hepatic tumorigenesis via disrupting the MDM2–p53 interaction

    N. S. Thomas, K. George and A. A. A. Selvam, Food Funct., 2018, 9, 5336
    DOI: 10.1039/C8FO01111G

Search articles by author

Spotlight

Advertisements